How much funding has Acelink Therapeutics raised?

Acelink Therapeutics has raised $800K in total funding, most recently a Seed round.

Who are Acelink Therapeutics's investors?

Acelink Therapeutics's investors include Kaitai Capital.

When was Acelink Therapeutics founded?

Acelink Therapeutics was founded in 2019.

Where is Acelink Therapeutics headquartered?

Acelink Therapeutics is headquartered in San Francisco, California, United States.

What industry is Acelink Therapeutics in?

Acelink Therapeutics operates in Biotech, Healthcare.

How many employees does Acelink Therapeutics have?

Acelink Therapeutics has 1-10 employees.

Acelink Therapeutics

San Francisco, United States · Founded 2019 · $800K raised

Biotech

Healthcare

Headquarters: San Francisco, California
Employees: 1–10
Founded: 2019
Business Model: B2B

Website: acelinktherapeutics.com
Total Funding: $800K
Last Round: $800K Seed
Rounds: 1

About

AceLink Therapeutics is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in the San Francisco Bay Area, focused on developing first-in-class therapies for rare genetic diseases driven by glycolipid biology. The company's lead programs include AL1211, a GCS inhibitor in Phase 2 trials for Fabry disease and Type I Gaucher disease; AL0804, a brain-penetrant GCS inhibitor targeting neuronopathic glycolipid storage diseases; and AL1311, an NRF2 activator for autosomal dominant polycystic kidney disease (ADPKD). AceLink leverages a lean, outsourced development model, collaborating with CROs, academic partners, and key opinion leaders to efficiently translate scientific discoveries into medicines. Its customers are patients and healthcare providers treating rare inherited metabolic and renal diseases.

Summary

Acelink Therapeutics is a Biotech company based in San Francisco, United States, founded in 2019. It has raised $800K in total across 1 round. Investors include Kaitai Capital.